Eugene Dayanghirang

Jaguar Health (NASDAQ: JAGX) (“Jaguar”) is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Napo Pharmaceuticals, a Jaguar company, focuses on developing and commercializing proprietary human pharmaceuticals from plants harvested responsibly from rainforest areas. Jaguar is the majority shareholder of Napo Therapeutics S.p.A., a corporation established by Jaguar in Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, focuses on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com. For more information about Magdalena Biosciences, visit magdalenabiosciences.com. To read our full social media policy, please visit https://jaguar.health/social-media-policy

Dialogue is a leading virtual care provider that empowers organizations to build healthier, happier, and more productive teams. Our high-touch health and well-being programs provide organizations and their members with tailored, measurable, and quality clinical care. Dialogues team of health professionals delivers exceptional experiences across the continuum of care, positively impacting millions worldwide. We foster thriving teams focused on health and well-being to improve culture, engagement, and productivity. Canada: • www.dialogue.co Programs: • Primary Care • Employee Assistance Program (EAP) • Mental Health+ • Wellness -- International: • www.dialogue.co/en-gb/ Programs: • Wellness • iCBT

Founded in 2012, Exaltare Capital Management is a consumer-oriented private equity firm with expertise in multi-unit and franchise businesses. We partner with lower middle market companies at a strategic inflection point. Since 2012, Exaltare has completed 17 platform and add-on transactions in multi-unit and franchised businesses, representing over 250 individual locations and over $900 million of capital. Our Investment Criteria: -Multi-unit and franchise businesses: Multi-unit and franchisor/franchisee businesses have unique characteristics, challenges, and opportunities, and our expertise in managing these issues for the benefit of multiple stakeholders in the space gives us a differentiated advantage. -Industry agnostic: We are experienced investors in industrial and business services, health and wellness, consumer goods and services, food and beverage, and personal care. -$2-$25M of EBITDA: We invest in high-potential small and medium sized companies. -North America: We invest in North American companies and support through global acquisition programs. -Control investments: We invest in both buyout and control equity situations with management rollover. -Strategic add-ons: We work with our portfolio companies to identify value-accretive add-on acquisitions of any size. At Exaltare, we believe that adding value is our most important contribution. We aim to add value in the following ways: -Strategic planning for rapid expansion -Acquisition strategy/execution -Experience serving in senior operating roles and deep network of Operating Affiliates -IT implementation -Management team development -Market expansion -Capital allocation and financing expertise to drive growth

325 Capital is a long-term, significant, minority owner of high-quality, small, public companies. We strive to collaborate with management teams and boards who are committed to driving long-term, fundamental value. As lead shareholders, we support our portfolio by working from deeply researched facts, acting as discrete advisors or constructive board members, providing access to a network of relationships, and providing direct growth capital. We have worked together for over 20 years developing this approach, strategy, and process. We value facts, transparency, alignment, and partnership.

Jaguar Health (NASDAQ: JAGX) (“Jaguar”) is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Napo Pharmaceuticals, a Jaguar company, focuses on developing and commercializing proprietary human pharmaceuticals from plants harvested responsibly from rainforest areas. Jaguar is the majority shareholder of Napo Therapeutics S.p.A., a corporation established by Jaguar in Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, focuses on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com. For more information about Magdalena Biosciences, visit magdalenabiosciences.com. To read our full social media policy, please visit https://jaguar.health/social-media-policy

Dialogue is a leading virtual care provider that empowers organizations to build healthier, happier, and more productive teams. Our high-touch health and well-being programs provide organizations and their members with tailored, measurable, and quality clinical care. Dialogues team of health professionals delivers exceptional experiences across the continuum of care, positively impacting millions worldwide. We foster thriving teams focused on health and well-being to improve culture, engagement, and productivity. Canada: • www.dialogue.co Programs: • Primary Care • Employee Assistance Program (EAP) • Mental Health+ • Wellness -- International: • www.dialogue.co/en-gb/ Programs: • Wellness • iCBT

Sagard is a global multi-strategy alternative asset management firm active in venture capital, private equity, private credit, and real estate. A full list of portfolio companies is available at: www.sagard.com/portfolio